Cellectar and NorthStar Partner to Advance Radiotherapy Development
Cellectar partners with NorthStar for Ac-225 supply, advancing CLR 121225 radiotherapy toward clinical trials.
Cellectar Biosciences has entered a 10-year agreement with NorthStar Medical Radioisotopes for a steady supply of non-carrier-added Actinium-225 (Ac-225), a rare and critical isotope for its CLR 121225 radiotherapeutic program. CLR 121225, which uses Cellectar’s Phospholipid Ether (PLE) delivery platform, has shown promise in preclinical studies targeting pancreatic and triple-negative breast cancers, among others.
This partnership addresses the limited global supply of Ac-225, enabling the progression of CLR 121225 to human clinical trials in 2025. The collaboration underlines a commitment to advancing alpha-emitting radiotherapies.
NorthStar’s expertise in producing high-purity Ac-225 ensures reliable support for Cellectar’s innovative therapeutic approach, which aims to bring first-in-class cancer treatments to market.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Curia New York recibe una carta de advertencia de la FDA por miles de inyecciones cromatográficas no documentadas
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Discussion